ArticleOncoimmunology2021

Durvalumab after concurrent chemotherapy and high-dose radiotherapy for locally advanced non-small cell lung cancer.

Yosef Landman et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.